Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Results Phys ; 31: 104895, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34722137

ABSTRACT

The COVID-19 outbreak has generated, in addition to the dramatic sanitary consequences, severe psychological repercussions for the populations affected by the pandemic. Simultaneously, these consequences can have related effects on the spread of the virus. Pandemic fatigue occurs when stress rises beyond a threshold, leading a person to feel demotivated to follow recommended behaviours to protect themselves and others. In the present paper, we introduce a new susceptible-infected-quarantined-recovered-dead (SIQRD) model in terms of a system of ordinary differential equations (ODE). The model considers the countermeasures taken by sanitary authorities and the effect of pandemic fatigue. The latter can be mitigated by fear of the disease's consequences modelled with the death rate in mind. The mathematical well-posedness of the model is proved. We show the numerical results to be consistent with the transmission dynamics data characterising the epidemic of the COVID-19 outbreak in Italy in 2020. We provide a measure of the possible pandemic fatigue impact. The model can be used to evaluate the public health interventions and prevent with specific actions the possible damages resulting from the social phenomenon of relaxation concerning the observance of the preventive rules imposed.

2.
Dig Liver Dis ; 49(6): 676-682, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28179097

ABSTRACT

BACKGROUND: Use of grafts from very old donors for liver transplantation is controversial. AIM: To compare the perioperative course of patients receiving liver grafts from young ideal vs octogenarian donors. METHODS: Analysis of the perioperative course of patients receiving liver grafts from young, ideal (18-39 years) vs octogenarian (≥80years) deceased donors between 2001 and 2014. RESULTS: 346 patients were studied: 179 (51.7%) received grafts aged 18-39 years whereas 167 (48.3%) received a graft from a donor aged ≥80years. Intra-operative cardiovascular (p=0.2), coagulopathy (p=0.5) and respiratory (p=1.0) complications and incidence of reperfusion syndrome (p=0.3) were similar. Patients receiving a young graft required more fresh frozen plasma units (p≤0.03) but did not differ for the need of packed red cells (p=0.2) and platelet (p=0.3) transfusions. Median ICU stay was identical (p=0.4). Patients receiving octogenarian vs young grafts did not differ in terms of death or re-transplant (p=1.0) during the ICU stay. Similar cardiovascular, respiratory, renal, infectious and neurological postoperative complication rates were observed in the two groups. CONCLUSIONS: Octogenarian donors in liver transplantation grant an equivalent perioperative course to ideal young donors.


Subject(s)
Age Factors , Donor Selection/standards , Liver Transplantation , Postoperative Complications/epidemiology , Adolescent , Adult , Aged, 80 and over , Blood Transfusion , Databases, Factual , Female , Graft Survival , Humans , Italy , Logistic Models , Male , Multivariate Analysis , Perioperative Care , Retrospective Studies , Risk Factors , Young Adult
3.
J Anesth ; 29(3): 426-432, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25433498

ABSTRACT

PURPOSE: Acute kidney injury remains a serious complication after orthotopic liver transplantation. To date, several 'renal-protective' agents have been explored in this setting but with conflicting and disappointing results. Therefore, our aim is to evaluate the effects of fenoldopam in liver transplant patients with an established renal injury. METHODS: In this prospective study, intravenous fenoldopam 0.1 µg/kg/min was administered to consecutive liver transplant patients with postoperative (within 7 days from surgery) stage 2 acute kidney injury (AKI) according to the Acute Kidney Injury Network classification. Actual glomerular filtration rate (GFR; calculated by the iohexol plasma clearance), serum creatinine (SCr) and cystatin C (SCyC) were used to assess the effect of the medication on the patients. RESULTS: During the study, 295 patients underwent liver transplant. Fifty-one patients (17.6%) met the inclusion criteria and the data from 48 patients were analysed. SCr and SCyC levels decreased (p < 0.001 after 48 h; p < 0.0001 after 72 h) and GFR increased (p < 0.001 after 24 h; p < 0.0001 after 72 h). When compared to a cohort of comparable patients with AKI from our historical series, the patients in the present study showed better SCr and SCyC levels. It was not necessary to discontinue the infusion of fenoldopam in any patient because of the occurrence of adverse events potentially attributable to it. CONCLUSION: We showed that fenoldopam was capable of improving some renal function parameters in postoperative liver transplantation patients with on-going AKI. This preliminary study now sets the stage for a multicenter, randomized, placebo-controlled trial in order to provide definite evidence.


Subject(s)
Acute Kidney Injury/drug therapy , Fenoldopam/administration & dosage , Liver Transplantation/adverse effects , Acute Kidney Injury/etiology , Creatinine/metabolism , Cystatin C/metabolism , Female , Glomerular Filtration Rate/drug effects , Humans , Kidney Function Tests , Male , Middle Aged , Postoperative Period , Prospective Studies
4.
Anesth Analg ; 113(3): 515-22, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21680855

ABSTRACT

BACKGROUND: Reliable cardiac output monitoring is particularly useful in the cirrhotic patient undergoing liver transplant surgery, because cirrhosis of the liver is associated with a vasodilated and high output state, known as cirrhotic cardiomyopathy, that challenges the reliability of pulse contour cardiac output technology. The contractility of the ventricle in cirrhosis is impaired, which is tolerated even though the ejection fraction and cardiac output are elevated because of the low peripheral resistance. However, during surgery the cirrhotic patient can decompensate because of the physiological changes and stress of surgery. Recently, we showed that the FloTrac/Vigileo™ failed to perform in cirrhotic patients undergoing transplant surgery. In response, the company upgraded their software. Therefore, we have assessed the accuracy and reliability of this new third-generation (version 3.02) FloTrac/Vigileo algorithm software in the same setting. METHODS: The cardiac index was measured simultaneously by single-bolus thermodilution (CI(TD)), using a pulmonary artery catheter, and pulse contour analysis, using the FloTrac/Vigileo (CI(V)). Readings were made at 10 time points during and after liver transplant surgery in 21 patients. Comparisons with data from our 2009 study, which used second-generation (version 01.10) software, were also made. RESULTS: Our new data show that version 3.02 software significantly reduced the adverse effect on pulse contour cardiac output reading bias in low peripheral resistance states, and thus improves the overall precision and trending ability of the system. Regression analysis between CI(TD) and CI(V) showed that the correlation was moderate (r =0.67, 95% confidence interval, 0.40 to 0.86). The Bland and Altman analysis showed that bias was 0.4 L.min(-1) · m(-2), and the percentage error was 52% (95% confidence interval, 49% to 55%). Trending ability of the new software also was improved but was still well below the current benchmarks. CONCLUSION: The new software (version 3.02) provided substantial improvements over the previous versions with better overall precision and trending ability. Further algorithm refinements will increase this technology's reliability to be extensively used in the highly complex setting of cirrhotic patients undergoing liver transplantation.


Subject(s)
Blood Pressure , Cardiac Output , Cardiomyopathies/physiopathology , Catheterization, Peripheral/instrumentation , Liver Cirrhosis/surgery , Liver Transplantation , Monitoring, Intraoperative/instrumentation , Radial Artery/physiopathology , Software , Adult , Algorithms , Cardiomyopathies/etiology , Catheterization, Swan-Ganz , Equipment Design , Female , Humans , Italy , Liver Cirrhosis/complications , Liver Cirrhosis/physiopathology , Liver Transplantation/adverse effects , Male , Middle Aged , Predictive Value of Tests , Regression Analysis , Reproducibility of Results , Signal Processing, Computer-Assisted , Thermodilution , Time Factors
5.
Transfus Apher Sci ; 43(2): 167-70, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20691639

ABSTRACT

Thrombotic thrombocytopenic purpura (TTP) is associated with high mortality rates. TTP may have various and different presentations depending on the organs involved. It is now recognized to be the consequence of reduction of blood levels of the disintegrin and metalloprotease with thrombospondin motifs (ADAMTS)-13. Prompt diagnosis of TTP is paramount, because plasma exchange is the only treatment capable of improving patient's survival with a dual mechanism: removal of anti-ADAMTS-13 auto-antibodies and infusion of the active protease available in the fresh frozen plasma. We report herein on the challenges in diagnosing TTP-like complications of post-surgical facial surgery in a young male patient.


Subject(s)
Purpura, Thrombotic Thrombocytopenic/diagnosis , ADAM Proteins/blood , ADAMTS13 Protein , Adult , Autoantibodies/chemistry , Cryopreservation , Face/surgery , Follow-Up Studies , Humans , Male , Plasma/metabolism , Plasma Exchange/methods , Postoperative Complications/diagnosis
6.
Clin Transplant ; 23(6): 853-60, 2009.
Article in English | MEDLINE | ID: mdl-19220362

ABSTRACT

The aim of the present work was to assess the incidence of neuro-nephrotoxicity after a single-staggered dose of calcineurin inhibitors (CI) with different immunosuppressive approaches. From January to December 2006, all liver transplantation (LT) recipients at risk of renal or neurological complications treated with extracorporeal photopheresis (ECP) + mycophenolate mofetil + steroids and staggered introduction of CI (ECP group) were compared with a historical control group on standard CI-based immunosuppression. The ECP group included 24 patients with a mean model for end-stage liver disease (MELD) score of 19.9 +/- 11.1. The control group consisted of 18 patients with a mean MELD score of 12.5 +/- 5.2 (p = 0.012). In the ECP group CI were introduced at a mean of 9.2 +/- 6.2 d (4-31 d) after LT. Five patients in the ECP group presented acute neuro-nephrotoxicity after the first CI administration on post-transplant d 4, 5, 6, 6, and 14. Overall patient survival at one, six, and 12 months was 100%, 95.8%, and 95.8% in the ECP group vs. 94.4%, 77.7%, and 72.2% in the control group (p < 0.001). In conclusion, we showed that CI toxicity may occur after a single-staggered dose administration, ECP seems to be a valuable tool for managing CI-related morbidity regardless of the concomitant immunosuppressive regimen, being associated with a lower mortality rate in the early post-transplant course.


Subject(s)
Calcineurin Inhibitors , Central Nervous System Diseases/chemically induced , Graft Rejection/drug therapy , Immunosuppressive Agents/adverse effects , Kidney Diseases/chemically induced , Liver Transplantation , Calcineurin/blood , Central Nervous System Diseases/enzymology , Central Nervous System Diseases/therapy , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Graft Rejection/enzymology , Humans , Immunosuppressive Agents/administration & dosage , Kidney Diseases/enzymology , Kidney Diseases/therapy , Liver Failure/surgery , Male , Middle Aged , Photopheresis/methods , Postoperative Period , Prognosis , Prospective Studies , Risk Factors , Time Factors
7.
Transpl Int ; 18(12): 1356-60, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16297054

ABSTRACT

This study aims to evaluate and compare the early outcome of both pancreas-alone transplantation (PTA) and simultaneous kidney-pancreas transplantation (SPKT) focusing on the complications affecting the first month after the procedures. The records of all patients who underwent PTA or SPKT were reviewed. We considered the length of ICU stay, the need for postoperative ventilatory support, hemodynamic and metabolic data (arterial pH, serum glucose, need for exogenous insulin), infectious diseases incidence, microbiological colonization rate and any kind of postoperative complication arising during the first month after the transplantation. PTA recipients underwent a quicker surgery (P < 0.01) with shorter ICU stay (P < 0.05) and a lower need for postoperative mechanical ventilation (P < 0.05). They also had a higher hemodynamic stability (P < 0.05) with less cardiological complications (P < 0.05) in the intra- and postoperative phases; bacterial colonisation was also less frequent in PTA recipients (P < 0.05). On the contrary, no significant difference was noted with regard to postoperative nausea/vomiting, sudden myocardial death, ICU re-admissions, graft function, rate of rejection, grafts explantation and re-transplantation. PTA could be considered as preemptive for severe diabetic complications in patients with long-lasting severe type I diabetes. However, establishing the correct timing of PTA is of paramount importance in order not to expose the patients early to risks arising from a major surgery and heavy immunosuppressive treatments.


Subject(s)
Kidney Transplantation/adverse effects , Kidney Transplantation/methods , Pancreas Transplantation/adverse effects , Pancreas Transplantation/methods , Adult , Blood Glucose/metabolism , Female , Graft Rejection , Graft Survival , Hemodynamics , Humans , Hydrogen-Ion Concentration , Immunosuppressive Agents/pharmacology , Immunosuppressive Agents/therapeutic use , Insulin/metabolism , Intensive Care Units , Male , Middle Aged , Morbidity , Time Factors , Treatment Outcome
8.
Liver Transpl ; 10(8): 986-92, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15390323

ABSTRACT

With the aim of assessing whether fenoldopam can help to preserve renal function after liver transplantation, we randomized 140 consecutive recipients with comparable preoperative renal function to receive fenoldopam 0.1 microg/kg/minute (group F, 46 patients), dopamine 3 microg/kg/minute (group D, 48 patients), or placebo (group P, 46 patients) from the time of anesthesia induction to 96 hours postoperatively. There were no differences between the groups in intraoperative urinary output or furosemide administration (both P =.1). Daily recordings made during the first 4 postoperative days revealed no significant differences in urinary output (P =.1), serum creatinine (P =.5), the incidence of renal insufficiency (P =.7), the need for loop diuretics (P =.9) or vasoactive drugs (P =.8). In comparison with preoperative levels, creatinine clearance at the end of the study in the patients receiving fenoldopam remained substantially unchanged, whereas it decreased by 39 and 12.3%, respectively, in the subjects receiving placebo or dopamine (P <.001); blood cyclosporine A (CsA) levels were similar in the 3 groups (P =.1). Three subjects died in the intensive care unit (1 in each group, P =.9), 2 of them had renal failure. In conclusion, our results confirm the inefficacy of dopamine in preventing or limiting early renal dysfunction after liver transplantation, and suggest that fenoldopam may preserve creatinine clearance by counterbalancing the renal vasoconstrictive effect of CsA, as it has been reported in previous experimental studies.


Subject(s)
Dopamine Agonists/therapeutic use , Fenoldopam/therapeutic use , Kidney Diseases/etiology , Liver Transplantation/pathology , Postoperative Complications/prevention & control , Recombinant Fusion Proteins , Adult , Antibodies, Monoclonal/therapeutic use , Basiliximab , Creatinine/blood , Cyclosporine/blood , Cyclosporine/therapeutic use , Dopamine/administration & dosage , Dopamine/therapeutic use , Drug Therapy, Combination , Female , Fenoldopam/administration & dosage , Furosemide/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Infusions, Intravenous , Kidney Diseases/prevention & control , Liver Transplantation/physiology , Male , Methylprednisolone/therapeutic use , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...